Drug intelligence / Profile preview

XJ-PLT-001

Development stage: Preclinical
Lead developer: HemaCell Biotechnology
Modality: Cell Therapies
Administration: Intravenous

Overview

XJ-PLT-001 is an in vitro-regenerated platelet injection cell therapy being developed by Suzhou Xueji Biotechnology (also operating internationally as HemaCell Biotechnology). The therapy is produced from hematopoietic stem cells as the source cells without any gene editing, utilizing a serum-free, feeder-free, and immortalization-free directed differentiation system to generate high-quality, large-scale, and stable platelet cells for transfusion. XJ-PLT-001 is designed to address the clinical shortage of platelets and treat platelet-related disorders. It has received two Orphan Drug Designations (ODD) from the U.S. FDA for the treatment of Bernard-Soulier syndrome (BSS) and congenital amegakaryocytic thrombocytopenia (CAMT).

Other names: Platelets produced in vitro from proplatelets derived from peripheral blood

Beyond the preview

Go deeper on XJ-PLT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XJ-PLT-001.